How to Get Testosterone Enanthate in Delaware

Delaware Law Permits Telehealth Testosterone Prescribing

Delaware residents can obtain a testosterone enanthate prescription through a telehealth visit without an in-person exam. The Delaware Board of Medical Licensure and Discipline recognizes telemedicine-delivered care as equivalent to in-person encounters when providers follow standard-of-care protocols. This means a Delaware-licensed physician, nurse practitioner, or physician assistant can evaluate labs, confirm a hypogonadism diagnosis, and write a Schedule III prescription during a video consultation.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with "unequivocally low serum testosterone levels and clinical signs and symptoms of androgen deficiency." That two-pronged requirement (low labs plus symptoms) applies regardless of whether the visit happens in a clinic or on a screen. Delaware's telehealth statute does not impose additional restrictions on controlled substance prescribing beyond standard DEA and state pharmacy board requirements, though prescribers must hold an active Delaware Controlled Substances Registration.

For men who prefer in-person evaluations, endocrinologists, urologists, and primary care physicians across the state provide TRT services. New Castle County has the highest concentration of prescribers, but telehealth has made geography largely irrelevant. A patient in Sussex County receives the same clinical evaluation as one in Wilmington.

What Labs You Need Before Starting

Two morning blood draws confirming total testosterone below 300 ng/dL are the diagnostic standard. One draw is not enough. The Endocrine Society guideline specifies that the measurement should occur between 7:00 AM and 11:00 AM because testosterone follows a circadian rhythm, peaking in the early morning and dropping by as much as 35% by late afternoon [1].

A standard pre-TRT lab panel includes:

• Total testosterone (two separate morning fasting draws)
• Free testosterone (calculated or equilibrium dialysis)
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to distinguish primary from secondary hypogonadism
• Complete blood count (CBC) with hematocrit baseline
• Comprehensive metabolic panel (CMP)
• Lipid panel
• Prostate-specific antigen (PSA) for men over 40
• Prolactin if secondary hypogonadism is suspected

Quest Diagnostics and Labcorp both operate draw stations across Delaware, with locations in Wilmington, Dover, Newark, and Middletown. Most telehealth TRT providers send lab orders directly to one of these networks. Results typically return within 48 to 72 hours.

The American Urological Association (AUA) defines testosterone deficiency as a total testosterone level below 300 ng/dL and states that "clinicians should use a total testosterone level below 300 ng/dL as a reasonable cut-off in support of the diagnosis of low testosterone" [2]. This threshold aligns with the Endocrine Society cutoff and is the standard most Delaware prescribers follow.

The Prescription Process Step by Step

Getting testosterone enanthate in Delaware follows a predictable sequence. Here is what to expect.

Step 1: Initial consultation. A telehealth or in-person provider reviews your symptoms (fatigue, reduced libido, mood changes, decreased muscle mass) and medical history. The provider orders labs if you do not already have qualifying bloodwork.

Step 2: Lab confirmation. Two morning total testosterone readings below 300 ng/dL, combined with symptoms, confirm hypogonadism. The provider reviews your CBC, PSA, and metabolic markers to rule out contraindications.

Step 3: Prescription. The provider writes a prescription for testosterone enanthate, typically 100 to 200 mg intramuscularly once weekly. Because testosterone enanthate is a Schedule III controlled substance under the Controlled Substances Act, the prescription must include the provider's DEA number and cannot exceed a 90-day supply without a refill authorization.

Step 4: Pharmacy dispensing. The prescription routes to a retail pharmacy (CVS, Walgreens, Rite Aid) or a licensed 503A compounding pharmacy. Dispensing typically takes 1 to 3 business days at retail and 3 to 7 business days from a compounding pharmacy that ships.

Step 5: Injection training. Most providers offer a brief injection training session (in-person or via video) to teach proper intramuscular or subcutaneous technique using a 25-gauge needle. Some patients self-inject at home; others visit a clinic for administration.

The total elapsed time from first consultation to first injection ranges from 7 to 14 days for most Delaware patients, depending on lab turnaround and pharmacy processing.

Testosterone Enanthate Dosing and What the Evidence Shows

The standard starting dose of testosterone enanthate for adult male hypogonadism is 50 to 400 mg intramuscularly every 2 to 4 weeks according to the FDA-approved prescribing information, though modern clinical practice favors more frequent, lower-dose protocols. Most TRT clinicians now prescribe 100 to 200 mg weekly or 50 to 100 mg twice weekly to minimize the peak-trough fluctuations that cause mood swings and energy dips.

The landmark Testosterone Trials (TTrials), published in the New England Journal of Medicine in 2016 (N=790 men aged 65 and older), demonstrated that testosterone gel therapy for one year improved sexual function, walking distance, and mood compared to placebo [3]. While the TTrials used a transdermal formulation, the physiological target was identical: mid-normal testosterone levels of 400 to 700 ng/dL. Enanthate injections achieve this same target with greater dose precision and lower cost.

A 2019 meta-analysis of 35 randomized controlled trials (N=5,601) published in JAMA Internal Medicine found that testosterone therapy was associated with improved sexual desire (standardized mean difference 0.41 to 95% CI 0.31 to 0.52) and erectile function compared to placebo [4]. The effect was consistent across injection and transdermal formulations.

The half-life of testosterone enanthate is approximately 4.5 days when administered intramuscularly in an oil carrier. This pharmacokinetic profile supports once-weekly or twice-weekly dosing. Dr. Abraham Morgentaler, associate clinical professor of urology at Harvard Medical School, has noted: "Weekly injections of testosterone enanthate provide the most stable blood levels and the fewest side effects for most men on TRT."

Who Can Prescribe in Delaware: MD vs. NP vs. PA

Delaware grants prescriptive authority for Schedule III controlled substances to multiple provider types. All three can legally prescribe testosterone enanthate.

Physicians (MD/DO) have unrestricted prescriptive authority for controlled substances when holding a valid DEA registration and Delaware Controlled Substances Registration. Endocrinologists and urologists prescribe TRT most frequently, but family medicine and internal medicine physicians do so regularly.

Nurse Practitioners (APRNs) in Delaware practice under a collaborative agreement with a physician for the first two years, after which they gain independent prescriptive authority per 24 Del. Code § 1906. An APRN with independent practice authority can prescribe testosterone enanthate without physician co-signature.

Physician Assistants (PAs) prescribe under a collaborative agreement with a supervising physician. The agreement must specifically authorize Schedule III prescribing. PAs commonly work in urology and primary care practices where TRT is a regular part of the panel.

For telehealth encounters, the prescriber must hold a Delaware medical license regardless of where they are physically located. Some national telehealth TRT platforms employ providers licensed in all 50 states, which simplifies access for Delaware residents.

Delaware Medicaid and Insurance Coverage

Delaware Medicaid covers testosterone enanthate for the treatment of male hypogonadism, but requires prior authorization (PA). The PA process confirms the medical necessity of the prescription and typically requires documentation of:

• Two morning total testosterone levels below 300 ng/dL
• Clinical signs and symptoms of hypogonadism
• Exclusion of reversible causes (opioid use, obesity-related suppression, pituitary pathology)
• No active contraindications (untreated prostate cancer, hematocrit above 54%, untreated sleep apnea)

Processing time for a Delaware Medicaid PA is typically 3 to 5 business days. Denials can be appealed with additional clinical documentation.

For commercially insured patients, most plans cover brand-name testosterone enanthate (Delatestryl) and generic formulations with a standard specialty or generic-tier copay. A GoodRx analysis of testosterone pricing shows that generic testosterone enanthate (200 mg/mL, 5 mL vial) costs approximately $30 to $90 at retail pharmacies without insurance, making it one of the most affordable TRT options available [5].

Compounded testosterone enanthate from a 503A pharmacy may cost $50 to $120 per month depending on concentration and volume. Insurance rarely covers compounded formulations, but the out-of-pocket cost remains competitive with retail generics.

503A Compounding Pharmacies in Delaware

Delaware licenses 503A compounding pharmacies to prepare patient-specific prescriptions, including testosterone enanthate in customized concentrations. A 503A pharmacy compounds medication based on an individual prescription from a licensed provider, as distinguished from 503B outsourcing facilities that produce bulk sterile preparations.

The FDA's guidance on compounding requires 503A pharmacies to compound in response to a valid, patient-specific prescription and to comply with USP 797 sterile compounding standards. Delaware's Board of Pharmacy enforces these federal standards and conducts routine inspections.

Compounded testosterone enanthate offers several advantages for some patients. Prescribers can specify exact concentrations (e.g., 200 mg/mL in grapeseed oil rather than the standard cottonseed oil carrier) to accommodate allergies or preferences. Some patients who experience injection-site irritation with the commercially manufactured product tolerate a compounded alternative with a different oil base.

Delaware-licensed 503A pharmacies can ship compounded testosterone enanthate directly to a patient's home within the state. For out-of-state compounding pharmacies to ship into Delaware, they must hold a Delaware non-resident pharmacy license.

Monitoring and Follow-Up on TRT

Starting testosterone enanthate is not a one-time event. Ongoing monitoring is clinically required. The Endocrine Society guideline recommends follow-up labs at 3 months, 6 months, and then annually [1].

Key monitoring parameters include:

• Total testosterone (drawn at trough, the morning before the next injection): target 400 to 700 ng/dL
• Hematocrit: testosterone stimulates erythropoiesis, and levels above 54% require dose reduction or temporary cessation. The TRAVERSE trial (N=5,246), the largest cardiovascular safety trial of testosterone therapy, found that polycythemia (hematocrit above 54%) occurred in 3.5% of testosterone-treated men versus 0.4% on placebo [6]
• PSA: a rise of more than 1.4 ng/mL within 12 months warrants urologic referral
• Estradiol: monitored if gynecomastia or water retention develops
• Lipid panel: annual reassessment

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, provided reassuring cardiovascular safety data. The trial demonstrated that testosterone replacement in men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo (hazard ratio 0.99 to 95% CI 0.81 to 1.21) [6]. Dr. Shalender Bhasin, principal investigator of TRAVERSE and professor of medicine at Harvard Medical School, stated: "These findings should provide reassurance to clinicians and patients that testosterone replacement therapy, when appropriately prescribed, does not increase cardiovascular risk."

Transferring a Prescription to Delaware

Patients relocating to Delaware or visiting from another state can transfer an existing testosterone enanthate prescription. Because testosterone enanthate is a Schedule III controlled substance, the transfer must comply with DEA regulations.

The key rule: a Schedule III prescription can be transferred between pharmacies only once. If the prescription has already been transferred, the original prescriber must issue a new prescription to a Delaware pharmacy. Multi-state retail chains (CVS, Walgreens) can often process transfers internally between their locations.

For patients on a telehealth TRT program, the provider simply sends a new prescription to a Delaware pharmacy. No formal transfer is needed. The provider must verify that their license covers Delaware practice.

Patients who move to Delaware permanently should establish care with a Delaware-licensed prescriber within 90 days. While an out-of-state prescription can be filled at a Delaware pharmacy, ongoing refills require a prescriber licensed in the state or holding telehealth privileges that cover Delaware.

Contraindications and Safety Considerations

Not every patient with low testosterone qualifies for treatment. The FDA's 2015 safety communication cautioned against prescribing testosterone solely for age-related decline without a confirmed pathological diagnosis [7]. Absolute contraindications include:

• Known or suspected prostate cancer or male breast cancer
• Hematocrit above 54% at baseline
• Untreated severe obstructive sleep apnea
• Uncontrolled heart failure (NYHA Class III or IV)
• Desire for near-term fertility (testosterone suppresses spermatogenesis)

Men planning to conceive should discuss alternatives such as enclomiphene or human chorionic gonadotropin (hCG) with their provider. Testosterone enanthate suppresses the hypothalamic-pituitary-gonadal axis, reducing sperm production to near-zero levels in most men within 3 to 6 months of initiation.

Delaware prescribers are expected to screen for these contraindications before initiating therapy. The pre-treatment lab panel (CBC, PSA, metabolic panel) serves as both a diagnostic and safety checkpoint. A baseline hematocrit of 52% or higher, for example, warrants a hematology workup before starting testosterone.